Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas S Heitmann

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Immunotargets and Therapy|May 7, 2026
B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile CancerAleksander Kielbik, Veronika Bahlinger, Christian M Schürch, et al.
Blood Cancer Journal|April 18, 2024
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibodySylwia A Stefańczyk, Ilona Hagelstein, Martina S Lutz, et al.
Frontiers in Oncology|April 5, 2021
Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer ProgressionClemens Hinterleitner, Yanjun Zhou, Claudia Tandler, et al.
Frontiers in Immunology|April 11, 2025
CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemiaBoris Klimovich, Leonard Anton, Jinwon Jung, et al.
Frontiers in Immunology|September 28, 2020
Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic LeukemiaMelanie Märklin, Alexander R Fuchs, Claudia Tandler, et al.
Annals of Hematology|January 19, 2022
Identification of CD105 (endoglin) as novel risk marker in CLLSarah M Greiner, Melanie Märklin, Samuel Holzmayer, et al.
Frontiers in Oncology|February 27, 2024
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)Susanne Jung, Richard F Schlenk, Christopher Hackenbruch, et al.
Journal of Leukocyte Biology|December 18, 2018
Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemiaDavid J Müller, Stefan Wirths, Alexander R Fuchs, et al.
Frontiers in Immunology|May 3, 2021
Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue SarcomasIlona Hagelstein, Martina S Lutz, Moritz Schmidt, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2021
Platelet-expressed immune checkpoint regulator GITRL in breast cancerYanjun Zhou, Jonas S Heitmann, Kim L Clar, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Immunotargets and Therapy|May 7, 2026
B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile CancerAleksander Kielbik, Veronika Bahlinger, Christian M Schürch, et al.
Blood Cancer Journal|April 18, 2024
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibodySylwia A Stefańczyk, Ilona Hagelstein, Martina S Lutz, et al.
Frontiers in Oncology|April 5, 2021
Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer ProgressionClemens Hinterleitner, Yanjun Zhou, Claudia Tandler, et al.
Frontiers in Immunology|April 11, 2025
CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemiaBoris Klimovich, Leonard Anton, Jinwon Jung, et al.
Frontiers in Immunology|September 28, 2020
Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic LeukemiaMelanie Märklin, Alexander R Fuchs, Claudia Tandler, et al.
Annals of Hematology|January 19, 2022
Identification of CD105 (endoglin) as novel risk marker in CLLSarah M Greiner, Melanie Märklin, Samuel Holzmayer, et al.
Frontiers in Oncology|February 27, 2024
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)Susanne Jung, Richard F Schlenk, Christopher Hackenbruch, et al.
Journal of Leukocyte Biology|December 18, 2018
Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemiaDavid J Müller, Stefan Wirths, Alexander R Fuchs, et al.
Frontiers in Immunology|May 3, 2021
Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue SarcomasIlona Hagelstein, Martina S Lutz, Moritz Schmidt, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2021
Platelet-expressed immune checkpoint regulator GITRL in breast cancerYanjun Zhou, Jonas S Heitmann, Kim L Clar, et al.
Pageof 7